Stryker Corp. appears to have resolved the sales and marketing problems that hindered its spine business in 2018 and now expects the growth of its neurotechnology and spine division to accelerate in 2020.
The company initially struggled to integrate the sales team from K2M after it acquired the spine-implant maker for $1.4bn in August 2018, but Stryker's leadership is now confident those challenges are under control